Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 4/2010

01-07-2010

Biomarkers of inflammation in heart failure

Authors: Biykem Bozkurt, Douglas L. Mann, Anita Deswal

Published in: Heart Failure Reviews | Issue 4/2010

Login to get access

Abstract

Heart failure (HF) is characterized by the elaboration of a portfolio of pro-inflammatory cytokines and inflammatory mediators that are considered to contribute to disease progression by virtue of the deleterious effects that these molecules exert on the heart and circulation. Recent studies have suggested that these inflammatory mediators may serve as relevant markers of disease severity and HF prognosis. Moreover, there is evidence that changes in the levels of inflammatory biomarkers may prove useful in following the change in patient clinical status following institution of appropriate HF therapy. This review will focus on the emerging role of inflammatory biomarkers, including pro-inflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with HF.
Literature
1.
Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMed
2.
Bozkurt B, Kribbs SB, Clubb FJ Jr et al (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382–1391PubMed
3.
Aukrust P, Ueland T, Muller F et al (1998) Elevated circulating levels of C–C chemokines in patients with congestive heart failure. Circulation 97:1136–1143PubMed
4.
Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988–998CrossRefPubMed
5.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206CrossRefPubMed
6.
Torre-Amione G, Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704–711PubMed
7.
Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP (2000) Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36:208–212CrossRefPubMed
8.
9.
Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL (1995) Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92:1487–1493PubMed
10.
Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72:561–566CrossRefPubMed
11.
Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK (1993) Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J 70:141–143CrossRefPubMed
12.
Katz SD, Rao R, Berman JW et al (1994) Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 90:12–16PubMed
13.
Aukrust P, Ueland T, Lien E et al (1999) Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376–382CrossRefPubMed
14.
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107:721–726CrossRefPubMed
15.
16.
Januzzi JL Jr, Peacock WF, Maisel AS et al (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50:607–613CrossRefPubMed
17.
Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ (1997) Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79:1426–1430CrossRefPubMed
18.
Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H (1993) Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 22:1897–1901CrossRefPubMed
19.
Ferrari R, Bachetti T, Confortini R et al (1995) Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92:1479–1486PubMed
20.
Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM (1996) Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77:723–727CrossRefPubMed
21.
MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S (1997) Circulating interleukin-6 in severe heart failure. Am J Cardiol 79:1128–1131CrossRefPubMed
22.
Loppnow H, Werdan K, Werner C (2002) The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist. Auton Autacoid Pharmacol 22:83–92CrossRefPubMed
23.
Seta Y, Kanda T, Tanaka T et al (2000) Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res Commun Mol Pathol Pharmacol 108:87–95PubMed
24.
Tsutamoto T, Hisanaga T, Wada A et al (1998) Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391–398CrossRefPubMed
25.
Dibbs Z, Thornby J, White BG, Mann DL (1999) Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 33:1935–1942CrossRefPubMed
26.
Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060–3067PubMed
27.
Vasan RS, Sullivan LM, Roubenoff R et al (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107:1486–1491CrossRefPubMed
28.
Deswal A, Petersen NJ, Feldman AM, White BG, Mann DL (2001) Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. Chest 120:453–459CrossRefPubMed
29.
Saraste A, Voipio-Pulkki LM, Heikkila P, Laine P, Nieminen MS, Pulkki K (2002) Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. Clin Chim Acta 320:65–67CrossRefPubMed
30.
Testa M, Yeh M, Lee P et al (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28:964–971CrossRefPubMed
31.
Anker SD, Ponikowski PP, Clark AL et al (1999) Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 20:683–693CrossRefPubMed
32.
McMurray J, Abdullah I, Dargie HJ, Shapiro D (1991) Increased concentrations of tumour necrosis factor in “cachectic” patients with severe chronic heart failure. Br Heart J 66:356–358CrossRefPubMed
33.
Niebauer J, Volk HD, Kemp M et al (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838–1842CrossRefPubMed
34.
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103:2055–2059PubMed
35.
Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL (2008) Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 118:625–631CrossRefPubMed
36.
Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243–249CrossRefPubMed
37.
Hansen MS, Stanton EB, Gawad Y et al (2002) Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 90:969–973CrossRefPubMed
38.
Nowak J, Rozentryt P, Szewczyk M et al (2002) Tumor necrosis factor receptors sTNF-RI and sTNF-RII in advanced chronic heart failure. Pol Arch Med Wewn 107:223–229PubMed
39.
Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H (1997) Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 61:657–664CrossRefPubMed
40.
Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY (2003) Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 33:941–948CrossRefPubMed
41.
Mohler ERIII, Sorensen LC, Ghali JK et al (1997) Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J Am Coll Cardiol 30:35–41CrossRefPubMed
42.
Maeda K, Tsutamoto T, Wada A et al (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587–1593CrossRefPubMed
43.
Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, Haass M (2002) Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 23:70–78CrossRefPubMed
44.
Ferrari R (2002) Interleukin-6: a neurohumoral predictor of prognosis in patients with heart failure: light and shadow. Eur Heart J 23:9–10CrossRefPubMed
45.
Wilson Tang WH, Francis GS, Morrow DA et al (2007) National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116:e99–e109CrossRef
46.
Hernandez-Presa M, Bustos C, Ortego M et al (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532–1541PubMed
47.
Wei GC, Sirois MG, Qu R, Liu P, Rouleau JL (2002) Subacute and chronic effects of quinapril on cardiac cytokine expression, remodeling, and function after myocardial infarction in the rat. J Cardiovasc Pharmacol 39:842–850CrossRefPubMed
48.
Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D (2001) Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk 8:279–282CrossRefPubMed
49.
Prabhu SD, Chandrasekar B, Murray DR, Freeman GL (2000) Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101:2103–2109PubMed
50.
Aronson D, Burger AJ (2001) Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. Ann Noninvasive Electrocardiol 6:98–106CrossRefPubMed
51.
de WI, Jaccard C, Corradin SB et al (1997) Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25:607–613
52.
Gage JR, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe DL (2004) Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 11:173–180CrossRefPubMed
53.
Matsumura T, Tsushima K, Ohtaki E et al (2002) Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol 39:253–257PubMed
54.
Ohtsuka T, Hamada M, Hiasa G et al (2001) Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37:412–417CrossRefPubMed
55.
Tsutamoto T, Wada A, Matsumoto T et al (2001) Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37:2086–2092CrossRefPubMed
56.
Gullestad L, Aukrust P, Ueland T et al (1999) Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34:2061–2067CrossRefPubMed
57.
Lemaitre JP, Harris S, Fox KA, Denvir M (2004) Change in circulating cytokines after 2 forms of exercise training in chronic stable heart failure. Am Heart J 147:100–105CrossRefPubMed
58.
Adamopoulos S, Parissis J, Karatzas D et al (2002) Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 39:653–663CrossRefPubMed
59.
Torre-Amione G, Stetson SJ, Youker KA et al (1999) Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 100:1189–1193PubMed
60.
Clark AL, Loebe M, Potapov EV et al (2001) Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J 22:2275–2283CrossRefPubMed
61.
Raymond RJ, Dehmer GJ, Theoharides TC, Deliargyris EN (2001) Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 141:435–438CrossRefPubMed
62.
Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101:2149–2153PubMed
63.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767–1772PubMed
64.
Joynt KE, Gattis WA, Hasselblad V et al (2004) Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 93:783–785CrossRefPubMed
65.
Rollins BJ, Yoshimura T, Leonard EJ, Pober JS (1990) Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 136:1229–1233PubMed
66.
Shioi T, Matsumori A, Kihara Y et al (1997) Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 81:664–671PubMed
67.
Behr TM, Wang X, Aiyar N et al (2000) Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 102:1315–1322PubMed
68.
Kolattukudy PE, Quach T, Bergese S et al (1998) Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 152:101–111PubMed
69.
Damas JK, Eiken HG, Oie E et al (2000) Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 47:778–787CrossRefPubMed
70.
71.
Pye M, Rae AP, Cobbe SM (1990) Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 63:228–230CrossRefPubMed
72.
Kaneko K, Kanda T, Yamauchi Y et al (1999) C-reactive protein in dilated cardiomyopathy. Cardiology 91:215–219CrossRefPubMed
73.
Milo O, Cotter G, Kaluski E et al (2003) Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol 92:222–226CrossRefPubMed
74.
Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C (2002) C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4:331–336CrossRefPubMed
75.
Cesari M, Penninx BW, Newman AB et al (2003) Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108:2317–2322CrossRefPubMed
76.
Haber HL, Leavy JA, Kessler PD, Kukin ML, Gottlieb SS, Packer M (1991) The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med 324:353–358PubMedCrossRef
77.
Parry EH (1961) The erythrocyte sedimentation rate in heart failure. Acta Med Scand 169:79–85PubMed
78.
Mcginnis AE, Lansche WE, Glaser RJ, Loeb LH (1953) Observations on the erythrocyte sedimentation rate in congestive heart failure. Am J Med Sci 225:599–604CrossRefPubMed
79.
Sharma R, Rauchhaus M, Ponikowski PP et al (2000) The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36:523–528CrossRefPubMed
80.
Bozkurt B, Mann DL (2003) Use of biomarkers in the management of heart failure: are we there yet? Circulation 107:1231–1233CrossRefPubMed
81.
Anand IS, Fisher LD, Chiang YT et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283CrossRefPubMed
82.
Milani RV, Mehra MR, Endres S et al (1996) The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest 110:992–995CrossRefPubMed
83.
Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534PubMed
84.
Nishigaki K, Minatoguchi S, Seishima M et al (1997) Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol 29:1214–1220CrossRefPubMed
85.
Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M (2008) Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54:752–756CrossRefPubMed
86.
Stenvinkel P, Andersson P, Wang T et al (1999) Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246:503–507CrossRefPubMed
Metadata
Title
Biomarkers of inflammation in heart failure
Authors
Biykem Bozkurt
Douglas L. Mann
Anita Deswal
Publication date
01-07-2010
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 4/2010
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-009-9140-3

Other articles of this Issue 4/2010

Heart Failure Reviews 4/2010 Go to the issue

OriginalPaper

Biomarker guided therapy for heart failure: focus on natriuretic peptides

OriginalPaper

Multi-marker strategies in heart failure: clinical and statistical approaches

OriginalPaper

Biomarkers in heart failure: a clinical review

EditorialNotes

Introduction: biomarkers in heart failure

OriginalPaper

Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases

OriginalPaper

Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits